Morand Eric F, Leech Michelle, Bernhagen Jürgen
Centre for Inflammatory Diseases, Monash Institute for Medical Research, 246 Clayton Road, Clayton, Victoria 3168, Australia.
Nat Rev Drug Discov. 2006 May;5(5):399-410. doi: 10.1038/nrd2029.
Macrophage migration inhibitory factor (MIF) is well established as a key cytokine in immuno-inflammatory diseases such as rheumatoid arthritis. Inflammation is now also recognized as having a crucial role in atherosclerosis, and recent evidence indicates that MIF could also be important in this disease. Here, we review the role of MIF in rheumatoid arthritis and atherosclerosis, discuss the ways in which MIF and its relationship with glucocorticoids could link these diseases, and consider the potential of MIF as a new therapeutic target for small-molecule and antibody-based anti-cytokine drugs.
巨噬细胞移动抑制因子（MIF）作为类风湿关节炎等免疫炎症性疾病中的关键细胞因子已得到充分证实。炎症现在也被认为在动脉粥样硬化中起关键作用，最近的证据表明MIF在这种疾病中也可能很重要。在这里，我们综述了MIF在类风湿关节炎和动脉粥样硬化中的作用，讨论了MIF及其与糖皮质激素的关系可能将这些疾病联系起来的方式，并考虑了MIF作为小分子和基于抗体的抗细胞因子药物新治疗靶点的潜力。
